# Press release

April 6th, 2020

---

# Grant awarded to sepsis prediction study

Stockholm-based AlgoDx, which focuses on supporting disease detection and prediction with machine learning, has been awarded a grant of 3 MSEK together with Skåne University Hospital and Uppsala University. This funding will cover the conduct of a clinical validation study of a sepsis prediction algorithm in intensive care.

- We are very proud to be backed by Vinnova through their SweLife and Medtech4Health call. This grant gives us significant funding to conduct the clinical validation study that has the potential to demonstrate that our product improves monitoring of sepsis risk in intensive care, says David Becedas, Director of Clinical Research.

## Swelife – For a competitive life science ecosystem in Sweden

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme's partners. We support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.

## Medtech4health

Medtech4Health is pushing for more medtech ideas and solutions to be implemented and be beneficial. Workingtogether with healthcare, academia and the business world, we create value for patients and a strengthenedmedical technology industry. Medtech4Health is funded by the government through Sweden's innovation agencyVinnova.

## About Sepsis and AlgoDx ExPRESS™

Sepsis can lead to multiple organ damage and is a potentially life-threatening condition that occurs when the body's response to fight an infection is out of balance. Sepsis affects more than 30 million people worldwide yearly, potentially leading to 6 million deaths. In sepsis treatment, the time factor is critical; where the cornerstones of intervention are early and appropriate antibiotics together with source control and fluid administration. Current detection methods for sepsis are incapable of early prediction. AlgoDx's solution lies in the deployment of the ML-based prediction algorithm ExPRESS that, using only parameters that are routinely collected on Electronic Health Records, accurately predicts sepsis in hospitalized patients.

## About AlgoDx

AlgoDx is a privately-owned company associated with Uppsala University. The company's mission is to bring clinically validated machine learning that saves lives and improves cost-effectiveness in healthcare to market.

AlgoDx AB, Bastugatan 12B, Stockholm, algodx.com
Press contact: David Becedas, CEO, Director of Clinical Research. Tel: +46 72 232 83 48.
Mail: david.becedas@algodx.com